T1177 New Onset IBD Occurring After Solid-Organ Transplantation

Tamaz, Raja; Bitton, Alain; Seidman, Ernest G.; Deschênes, Marc; Bouin, Mickaël; Marleau, Denis

doi:10.1016/s0016-5085(08)62336-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion Of Statement 211

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF antagonists have been used successfully to treat and prevent acute rejection in organ transplant recipients and to treat acute graft versus host disease (142,143). There are reports of patients developing inflammatory bowel disease following organ transplantation who were successfully treated with TNF inhibitors (144,145). As such, a TNF antagonist may assume a dual role in organ transplant recipients.…”

Section: Discussion Of Statement 21mentioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease

Sadowski

Bernstein²,

Bitton³

et al. 2009

Canadian Journal of Gastroenterology

Self Cite

View full text Add to dashboard Cite

In the past five years, tumour necrosis factor-alpha antagonist therapy has become a cornerstone in the management of moderate-to-severe Crohn's disease refractory to conventional treatment algorithms. The evidentiary base supporting the use of these drugs in Crohn's disease is substantial and strengthened by results from longterm clinical and molecular studies. However, significant gaps in knowledge exist, particularly with regard to treatment failure. Confidence in the safety of these drugs is increasing, provided that therapy is administered in a clinical setting in which potential complications can be readily recognized and treated.

show abstract